Clinical studies using stem cells for treatment of retinal diseases: state of the art
Cotrim CC., Jorge R., Oliveira MC., Pieroni F., Messias AMV., Siqueira RC.
Clinical Trial, published in Arq Bras Oftalmol (2020) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Clinical Trial
- Journal
- Arq Bras Oftalmol (2020)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 32159599
- PMCID
- PMC11826738
- DOI
- 10.5935/0004-2749.20200037
- Citations
- 8
Abstract (original English)
Degenerative retinal diseases such as retinitis pigmentosa, Stargardt's macular dystrophy, and age-related macular degeneration are characterized by irreversible loss of vision due to direct or indirect photoreceptor damage. No effective treatments exist, but stem cell studies have shown promising results. Our aim with this review was to describe the types of stem cells that are under study, their effects, and the main clinical trials involving them.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.